Gurnell, MarkDomingo, ChristianRabe, Klaus FMenzies-Gow, AndrewPrice, DavidBrusselle, GuyWechsler, Michael EXia, ChangmingDjandji, MichelGall, RebeccaJacobNara, Juby A.Rowe, Paul J.Deniz, YamoSiddiqui, Shahid2024-08-212024-08-212022-09Gurnell, M, Domingo, C, Rabe, K F, Menzies-Gow, A, Price, D, Brusselle, G, Wechsler, M E, Xia, C, Djandji, M, Gall, R, JacobNara, J A, Rowe, P J, Deniz, Y & Siddiqui, S 2022, 'Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab : LIBERTY ASTHMA TRAVERSE Study', Allergo Journal International, vol. 31, no. 6, P4.03, pp. 212. https://doi.org/10.1007/s40629-022-00225-62197-0378https://hdl.handle.net/2164/24079Acknowledgments and funding sources Data first presented at the 118th International Conference of the American Thoracic Society (ATS 2022); San Francisco, CA, USA; May 13–18, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Anthony Aggidis, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline. Alternate presenters: Anne Atenhan and Mayank Thakur.145035engR MedicineRJournal item10.1007/s40629-022-00225-6316